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Aim To evaluate the effect of genetic instability and deg-
radation in archived histology samples from cancerous tu-
mors and to investigate the validity of short tandem repeat 
(STR) typing of these samples and its potential effect on 
human identification.
Methods Two hundred and twenty eight slides of archival 
pathology tissues from 13 different types of malignant tu-
mors were compared with healthy tissues from the same 
individuals. DNA analysis was performed using standard 
techniques for forensic STR analysis, PowerPlex®16 and 
Identifiler® on 2 distinct sample sets. Genetic instability was 
assessed by comparing reference tissues with cancerous 
tissues derived from the same individual. Loss of heterozy-
gosity, a ≥50% reduction in heterozygosity ratio between 
healthy and diseased samples, and microsatellite insta-
bility, the presence of an additional allele not present in 
reference tissue, were assessed. The quality of profiles ob-
tained with respect to completeness among the archived 
samples and degradation using the 2 platforms were also 
compared.
Results Profiles obtained using the Identifiler® system 
were generally more complete, but showed 3-fold higher 
levels of instability (86%) than those obtained using Pow-
erPlex® 16 (27%). Instances of genetic instability were dis-
tributed throughout all loci in both multiplex STR systems.
Conclusion After having compared 2 widely used forensic 
chemistries, we suggest individual validation of each kit for 
use with samples likely to exhibit instability combined with 
fixation induced degradation or artifact. A “one size fits all” 
approach for interpretation of these samples among com-
mercially available multiplexes is not recommended.
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The analysis of human DNA polymorphisms is a valuable 
tool in genetic research and diagnostics and has become 
routine in clinical and forensic laboratories. It has aided 
in diagnosing diseases, determining paternity, identify-
ing human remains, and attributing biological specimens 
to a source. However, DNA analysis for identity testing is 
only useful if there is a reference sample to compare with 
the sample in question. In cases where no obvious ref-
erence is available, it is necessary to find an alternative 
source. Difficulty can arise when the authenticity of the 
reference sample is questionable, or when the sample is 
taken from tissues with possible genetic variability, such 
as a malignant tumor (1-7). Since a known characteristic of 
malignant tumors are permanent alterations in the DNA 
molecule, DNA from these cells can display numerous 
anomalies including microsatellite instability (MSI), char-
acterized by the presence of an additional allele or a size 
shift in an existing allele, deletions, or loss of heterozygos-
ity (LOH) (8-13). Short tandem repeats (STRs; microsatellite 
DNA) commonly examined in forensic identification are 
not thought to be linked to visible traits or pathologies 
and are considered relatively stable and well distributed 
in the population. To that effect, some profiles obtained 
from nuclear and mitochondrial DNA of malignant tis-
sues have been proven to be consistent with their normal 
counterparts. However, given the potential for pathologi-
cal variability through genetic instability, it is necessary to 
evaluate its effect on the validity of the nuclear DNA anal-
ysis for identity determination and if steps can be taken to 
abrogate its impact.
Clinical tissue samples are not usually employed in fo-
rensic casework, but can play a role in the identification 
of unknown bodies and paternity testing, as well as aid in 
resolving issues stemming from pathology mix-ups and 
contamination (1,2). Archival pathology specimens are 
carefully cataloged and widely available, given their use in 
diagnostics and are a potentially large source for forensic 
STR testing. STRs are relatively stable, but degradation may 
have an effect, especially when analyzing tissues which 
have been treated with highly aggressive chemicals (eg, 
formaldehyde, xylene, etc.) during typical histological pro-
cessing.
This research, conducted over a period of several years, 
analyzed and reviewed characteristics of DNA profiles ob-
tained by means of 2 different commercially available kits, 
which are widely used in forensic identification. These kits 
both contain the widely accepted “core loci,” recommend-
ed by the Federal Bureau of Investigation for use in foren-
sic DNA databases (http://www.promega.com/geneticid-
proc/eusymp2proc/17.pdf ). The aim of the study was to 
determine STR profile differences between healthy and 
pathologically altered tissues from the same source using 2 
widely used forensic multiplex polymerase chain reaction 
(PCR) tests. These genetic differences arise due to disease 
and can complicate the use of malignant tissues as refer-
ence samples in forensic biology. We also sought to deter-
mine if variations occur in the indicators of genetic insta-
bility (LOH and MSI) among different tumor types and to 
assess possible variations in genetic instability in the same 
tumor type. This information allows us to recommend in-
terpretation guidelines for the use of archived potentially 
diseased, and thus genetically unstable, material for hu-
man identification.
MAteriALS AnD MethoDS
Selection and collection of samples
A total of 228 samples, in the form of blocks of formalin 
fixed paraffin-embedded malignant tissues were exam-
ined and compared with healthy tissues from the same 
individuals. Thirteen different types of malignant tumors 
were represented in the study material: adenocarcino-
mas of the stomach, uterine endometrium, ovaries, lung, 
prostate, cecum, colon, pancreas, breast, and rectosigmoid 
colon; leiomyosarcomas of the uterus; ovarian papillary 
serous carcinomas from the uterine endometrium; endo-
metrial carcinomas; malignant melanomas from the skin; 
and hepatocellular carcinomas.
All tissues of interest were gathered from archival and 
waste formalin-fixed paraffin-embedded tissues and un-
derwent identical tissue fixation and paraffin embedding. 
The samples dated from 1 to 17 years before the study. Tis-
sues had been taken from the patients as part of routine, 
necessary diagnostic procedures in concordance with In-
stitutional Review Board approvals from the original insti-
tutions conducting the tests (Department of Pathology, 
University of Pennsylvania Presbyterian Medical Center, 
Philadelphia; Department of Pathology, NYU School of 
Medicine, New York; and NYC Department of Health and 
Mental Hygiene, New York).
The samples for this study were chosen according to tu-
mor type and no identifying information was retrieved in 
any step of the study. The tissue donors were not con-
tacted in any manner. Identifying and personal infor-
mation was not used in the data collection and 
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analysis with the exception of the type of tumor the pa-
tient was diagnosed with and the organ from which the 
tissue sample was obtained.
DNA and subsequent bio-statistical analysis was conduct-
ed at the Office of Chief Medical Examiner in New York City, 
Department of Forensic Biology.
experimental methods of analysis
Distribution of tumor types. Slides (n = 228) of healthy and 
tumor tissues were made from the formalin-fixed paraffin-
embedded tissue blocks, prepared with 5 µm thick sections 
(stained with hematoxylin-eosin or unstained), and separat-
ed so that the healthy tissues were never analyzed along-
side their tumor counterparts to prevent contamination.
One hundred and sixteen malignant tumor tissues and 
their healthy counterparts were analyzed, representing 13 
different tumor types (Table 1)
All tissues were submitted to DNA extraction, quantitation, 
PCR of STR regions using the indicated system, separation 
of amplified products by capillary electrophoresis, and 
comparative and statistical analysis.
Phenol-chloroform isoamyl alcohol (PCIA) extraction. This 
method of extraction was chosen based on previous expe-
rience and was proven as effective when a low amount of 
poor quality DNA was expected (2). Using a sterile scalpel, 
one slide for each sample was scraped into a tube (Eppen-
dorf, Hamburg, Germany) tube containing extraction buf-
fer (10mM Tris [pH 8.0], 50mM EDTA [pH 8.0], 100mM NaCl, 
and deionized H20), 20% SDS, 0.39M DTT, and Proteinase 
K (20 mg/mL) and incubated overnight in a shaking 56°C 
heat block. Appropriate extraction negatives were also in-
cluded, without tissue. After incubation, samples were cen-
trifuged for 5 minutes at 1000 rpm. The clear supernatant, 
along with an equal volume of phenol:chloroform:isoamyl 
alcohol (25:24:1), was transferred to an Eppendorf® Phase 
Lock Gel Tube (Eppendorf ) and centrifuged for 2 minutes 
at 13 000 rpm under a fume hood. The aqueous top layer 
was carefully transferred to a Microcon 100 column (Milli-
pore, Bedford, MA, USA) pre-moistened with TE-4. The col-
umns were centrifuged at 2500 rpm for 30 minutes. Addi-
tional centrifugation was added as necessary to filter the 
entire volume. After the liquid was discarded, TE-4 was add-
ed and the columns were centrifuged again. To elute the 
DNA, 40 µL of TE-4 was added to each column and the col-
umn was inverted into a new tube and centrifuged at 3500 
rpm for 3 minutes. The column was discarded and the final 
sample volume was brought to 100 µL in TE-4.
DNA quantitation. The Quantiblot® Kit (Applied Biosys-
tems) was used as per manufacturer’s instructions and val-
idated by Office of Chief Medical Examiner protocols for 
quantitation of all samples amplified in PowerPlex®16. For 
quantitation of samples amplified in Identifiler®, an Alu-re-
peat based real-time PCR was used (14).
PowerPlex® 16 STR amplification. Extracts were amplified 
using the PowerPlex® 16 multiplex system in the Gene-
Amp® PCR System 9700 (Applied Biosystems), following 
manufacturer’s protocol. The amount of template DNA 
added to the reaction mixture was dependent upon the 
QuantiBlot results, with an optimal concentration of 1 ng 
and a volume of 20 µL. A negative control was made with 
20 µL of TE-4 and a positive control was made with 10 µL 
of TE-4 and 10 µL of Positive Control DNA (Applied Biosys-
tems). The amplification reaction was run in the following 
conditions: 95°C for 11 minutes; 96°C for 1 minute; 95°C 
– 30 seconds/60°C – 30 seconds/70°C – 45 seconds for 10 
cycles; 94°C – 30 seconds/60°C – 30 seconds/70°C – 45-
second for 22 cycles; 70°C for 45 seconds; 60°C for 30 min-
utes; and 4°C until the end of the reaction.
Identifiler® STR amplification. Identifiler® multiplex PCR sys-
tem was used for STR analysis of 11 endometriod carcino-
ma, 9 papillary serous carcinomas, and 15 mixed adenocar-
cinoma samples, paired with histologically normal samples. 
A range of 500 pg/µL to 1000 pg/µL of DNA, as determined 
tABLe 1. tumor samples and healthy counterparts analyzed in 
PowerPlex® 16 and identifiler®





Papillary serous carcinoma  9
Melanoma  2
Hepatocellular carcinoma  2
Endometrial carcinoma  9





*Samples were taken from tumors of the stomach, uterine endome-
trium, lung, prostate, cecum, colon, rectosigmoid colon, pancreas, and 
breast.
†15 total cases were analyzed consisting of components 1 and 2.
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by real-time PCR, in 5 µL total volume was used in each 13-
µL reaction. Positive and negative controls were included 
in each amplification as for PowerPlex®16. The amplifica-
tion reaction was run in the following conditions: 95°C for 
11 minutes; 94°C – 1 minute/59°C – 2 minutes/72°C – 1 
minute) for 28 cycles; 60°C for 60 minutes; 4°C until the end 
of the reaction.
Separation of amplified products. The amplified products 
were separated using the ABI Prism® 3130 Genetic Analyz-
er (Applied Biosystems), following the manufacturer’s pro-
tocol.
DNA fragment length was determined by ABI’s Genescan® 
software (Applied Biosystems) by comparing samples with 
the ILS 600 (PowerPlex® 16), or LIZ500 (Identifiler®). Electro-
pherograms were generated and allelic designations were 
assigned using ABI’s Genotyper® software (Applied Biosys-
tems).
Assessment of genetic instability. Heterozygote ratio (HR) 
was determined using the formula: HR = A low/A high, 
where [A] is the allelic intensity in relative fluorescence 
units (RFU) (2,5,6). Microsatellite instability was identified 
by detection of abnormal alleles (allelic insertion, expan-
sion, or contraction) at the STR loci compared with the 
healthy tissue (5). Losses of heterozygosity (LOH), defined 
by a ≥50% reduction in HR between healthy and diseased 
samples, and in reference tissue, were assessed. Expressed 
mathematically, LOH ratios were calculated according to 
the formula: [A1/A2]diseased/[A1/A2]healthy, where a ratio be-
tween 0.51 and 1 indicates no change from the reference 
tissue. Ranges between 0.0-0.5 and ≥2 indicated LOH. 
Comparisons were made with respect to the intensity of 
the signal peak and the size of the fragments, as well as to 
peak balance/imbalance. LOH is especially an interesting 
phenomenon, due to the fact that it could be a result of 
degradation/alteration of DNA.
Statistical analysis
Pearson correlation test was used to compare allelic insta-
bility rates at STR loci with sample age, using Microsoft Ex-
cel (Microsoft, Redmond, WA, USA).
reSuLtS AnD DiSCuSSion
Working with archival, formalin-fixed paraffin-embedded 
tissues of malignant origin, presents potential challenges 
with respect to distinguishing sample degradation and 
procedural chemical alterations from genetic instability. 
Genetic instability can manifest as expansion, contraction, 
or loss of microsatellite DNA repetitive sequences.
With these issues in mind, samples were analyzed by 2 sep-
arate approaches, the first assessing the quality of profiles 
obtained using allele size and overall profile quality as indi-
cators, and the second assessing genetic instability known 
to occur in tumors. The potential presence of LOH is of par-
ticular concern, as it can mimic the allelic drop-out com-
monly seen due to sample degradation.
Distribution of profile quality
With respect to the amount of DNA obtained from sam-
ples, no difference was observed between healthy and 
tumor tissues. Each sample was amplified once using the 
amount of DNA validated for the specific multiplex sys-
tem. Similar to regular casework, in most instances there 
was not sufficient material to conduct multiple testes. Out 
of the 70 healthy samples tested by PowerPlex®16 multi-
plex system and the 1050 expected STR loci retrieved, 690 
(67.50%) yielded profiles. Among them, 89.42% were from 
loci ≤350 bp and 10.58% from loci >350 bp. Of the 70 tu-
mor samples tested by the same platform, out of the 1050 
expected loci, 722 (68.76%) yielded profiles. Among them, 
88.36% were from loci ≤350 bp and 11.64% from loci >350 
bp. The healthy samples had 21 loci (3.04%) with HR≤0.7 (3 
with HR≤0.45), while tumor samples had 122 loci (16.90%) 
with HR≤0.7 (36 with HR≤0.45). Most of these instances 
were from loci <350 bp.
In contrast, data obtained from the set of the samples am-
plified in Identifiler® did not show a strong association be-
tween locus size and HR (data not shown). Furthermore, 
350 bp would not be a useful size distinction for assessing 
results from this kit, as the allele range for Identifiler® loci is 
designed to be <360 bp and very few alleles are ≥350 bp.
For empirical analysis of profile quality, the following defi-
nitions were used: complete profile (all 15 loci), good pro-
file (8-14 loci), poor profile (1-7 loci), and negative profile 
(no loci) (15). Amelogenin was not considered in this analy-
sis, as Amelogenin-based sex determination is based on a 
6-bp intron insertion and not a microsatellite repeat.
For samples analyzed using PowerPlex®, of the 70 healthy 
profiles 29 were complete (41%), 18 were good (26%), 
13 were poor (19%), and 10 were negative (14%). Of 
the 70 tumor profiles, 31 were complete (44%), 21 
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were good (30%), 10 were poor (14%), and 8 were nega-
tive (11%). These results indicate that amplification quality 
is not affected by the presence of histologically abnormal 
tissue, and therefore tumor tissues may provide a compa-
rable number of loci for forensic analysis compared with 
their histologically normal counterparts.
Given this determination, additional 86 samples, distinct 
from those amplified with PowerPlex®, were amplified us-
ing Identifiler® and assessed considering both normal and 
tumor samples together. Fifty four samples gave complete 
profiles (63%), representing a 20% increase over samples 
amplified using PowerPlex®, 22 were good (26%), 4 were 
poor (5%), and 6 gave no profile (7%).
relationship between profile quality and sample age
The percentage of loci obtained for all the tissues stored 
for the 6 time intervals (1 year and 3-7 years) were as-
sessed. The correlation coefficient between percent loci 
obtained and sample age was -0.9239, where a value of 
>0.9 was considered significant (Figure 1). This suggests a 
strong negative correlation between sample age and am-
plification success using the PowerPlex® system. Therefore, 
where possible, samples which have been collected more 
recently should be given preference over older tissue sam-
ples when using this kit.
Conducting Identifiler® testing on samples with a storage 
time interval of 2 to 17 years post-collection, no significant 
linear relationship was observed correlating sample age 
to profile quality (correlation coefficient: -0.8284). Sam-
ples in the range of 2 to 5 years old gave 100% of the ex-
pected loci. In samples between 5 and 12 years old, some 
decrease in profile quality was observed, with a range of 
62% to 90% of loci obtained with a nonlinear relationship 
(Figure 2). Therefore, samples from 0-12 years old may be 
safely considered for forensic analysis in this system. Given 
that the single 17-year-old sample gave a negative profile, 
samples above 12 years of age should be considered more 
carefully in this system.
relationship between profile quality by locus
Figure 3 shows the percentage of profiles obtained from 
both healthy and tumor tissues at each STR locus using the 
PowerPlex® system. Profile quality per locus was assessed 
by dividing the number of loci obtained at each locus by 
the total number of profiles obtained for healthy and tu-
mor tissues, respectively. The quality of the amplification 
was unaffected by the disease state of the sample. Further-
more, it is clearly demonstrated that the percentage of the 
obtained loci is much higher for those of smaller size. In 
contrast, samples amplified in Identifiler® (Figure 4) plat-
form demonstrated a higher success rate for the larger loci, 
and less dramatic fall-off in quality with respect to locus 
size. Additionally, this set of samples did not show any sig-
nificant difference in profile quality between healthy and 
tumor samples and the results are presented for all sam-
ples together. It was clearly shown that the success rate for 
the same locus using 2 diverse multiplex platforms was dif-
ferent (Figure 5). We speculate that these differences may 
at least in part be due to components of each individual kit 
(buffers and primer sequences). Furthermore, the Power-
Figure 1.
Correlation between loci obtained using PowerPlex®16 Multiplex Str 
system and sample age. each data point shows the percentage of loci 
obtained (y-axis) for all samples of a specific age (x-axis). A linear nega-
tive correlation (r = 0.92) exists between sample age and amplification 
success.
Figure 2.
Correlation between loci obtained using identifiler® Multiplex Str sys-
tem and sample age. each data point shows the percentage of loci ob-
tained (y-axis) for all samples of a specific age (x-axis). Very weak linear 
correlation (r = 0.83) existed between sample age and profile quality in 
the identifiler® system.
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Plex® component of this study was conducted at least 1.5 
years before the Identifiler® component. Differences in the 
success rate between the 2 kits may be reflective of chem-
istry optimization issues which have since been addressed 
by the manufacturer.
Genetic instability of tested tumor samples
Genetic instability includes any change in the tumor sam-
ple that was not present in the healthy sample including 
MSIs (an additional allele present in the tumor profile that 
was not present in the healthy profile [Figure 6] or a sub-
stitution of one allele for another [Figure 7]) and LOH (the 
loss of an allele that was present in the healthy profile but 
not in the tumor profile) (Figures 8 and 9).
Genetic instabilities were observed in 29 out of 70 (41.4%) 
sets of profiles obtained by PowerPlex®16. Of the 38 ad-
enocarcinoma profiles from the 383 loci obtained, there 
were 37 MSIs (9.6%) and 16 LOHs (4.2%). Of the 9 endo-
metrial profiles from the 61 loci obtained, there were 7 
Figure 3.
Percentage of loci obtained for healthy and tumor profiles using Power-
Plex®16 Multiplex Str system. the percentage of loci obtained is shown 
as a function of the locus and is arranged in size order from the largest 
to the smallest by dye line (blue, green, yellow). Dark gray bars represent 
percentages for healthy tissue profiles and open bars represent percent-
ages for malignant tissue profiles.
Figure 4.
Percentage of loci obtained for profiles using identifiler® Multiplex Str 
system. the percentage of loci obtained is shown as a function of the 
locus and is arranged in size order from the largest to the smallest by 
dye line (blue, green, yellow, red). Bars represent all tissue samples (both 
healthy and tumor) analyzed in identifiler® Multiplex Str system.
Figure 5.
Comparison between percentages of loci obtained for all profiles ampli-
fied in identifiler® Multiplex Str system (closed bars) vs PowerPlex®16 
Multiplex Str system (open bars). the percentage of loci obtained is 
shown as a function of the locus and is arranged in size order from the 
largest to the smallest by dye line (blue, green, yellow, red). Loci not rep-
resented in a particular kit are not shown.
Figure 6.
example of microsatellite instability – the presence of an additional allele 
not found in the healthy reference (shown in boxed area). the electro-
pherogram represents a sample amplified in PowerPlex®16 and separat-
ed on ABi Prism® 3130 Genetic Analyzer. top line represents the healthy 
sample with corresponding tumor shown below. Peaks are labeled with 
allele call, size in base pairs, and height in relative fluorescent units.
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LOHs (11.5%). Of the 2 melanoma profiles from the 26 loci 
obtained, there were 4 MSIs (15.4%). Of the 9 papillary 
serous profiles from the 45 loci obtained, there were 3 
MSIs (6.7%). Of the 10 leiomyosarcoma profiles from the 
132 loci obtained, there was 1 LOH (0.8%). No specific tu-
mor type showed a significantly higher rate and/or type 
of genetic instability over others. However, in examining 
a larger sample set, these differences may become evi-
dent.
Using either the AmpFlSTR® SGM Plus or the AmpFlSTR® 
SGM Profiler PCR amplification kits (Applied Biosys-
tems) on 41 surgically removed gastrointestinal malignan-
cies, Vauhkonen et al (5) observed allelic instabilities in 28 
cases (68%). In our study, by means of PowerPlex®16, al-
lelic instabilities were observed in 29 out of 70 sets (41.4%). 
Twenty-two sets (31.4%) could not be analyzed because 
one or both of the profiles were inconclusive. Thus, 19 sets 
(27.1%) of healthy and tumor tissues had consistent geno-
types. This is consistent with the 32% of cases with identi-
cal genotypes observed by Vauhkonen et al (5).
In another study of solid tumors, Poetsch et al (6) also in-
cluded a new category, partial LOH (pLOH), in addition to 
LOH and MSI. They defined pLOH as a >50% decrease in 
tumor DNA peak height when compared with the same al-
lele in healthy DNA. Though they examined different types 
of tumors (solid tumors, lymph node metastases, and dis-
tant metastases), they observed 22% pLOH, 14% LOH, and 
26% MSI.
Events of genetic instability were uniformly distributed 
throughout all loci, and no significant differences were 
found in a specific tumor type. Between 1.8%-8.5% of un-
stable alleles per locus through all analyzed tumor groups 
were found. Therefore, it is not possible to predict which 
loci may be more unreliable than others in determining a 
match between test and exemplar samples. In routine fo-
rensic testing, the profile obtained from an exemplar, re-
gardless of LOH or MSI, would be compared with the test 
profile with the assumption no instability had taken place. 
Figure 7.
example of microsatellite instability – a size shift in an allele present in 
the healthy reference (shown in boxed area). electropherogram repre-
sents a sample amplified in PowerPlex®16 and separated on ABi Prism® 
3130 Genetic Analyzer. top line represents the healthy sample with cor-
responding tumor shown below. Peaks are labeled with allele call, size in 
base pairs, and height in relative fluorescent units.
Figure 8.
example of partial loss of heterozygosity (shown in boxed area). electro-
pherogram represents a sample amplified in PowerPlex®16 and separat-
ed on ABi Prism® 3130 Genetic Analyzer. top line represents the healthy 
sample with corresponding tumor shown below. Peaks are labeled with 
allele call, size in base pairs, and height in relative fluorescent units.
Figure 9.
example of complete loss of heterozygosity (shown in boxed area). 
electropherogram represents a sample amplified in PowerPlex®16 and 
separated on ABi Prism® 3130 Genetic Analyzer. top line represents the 
healthy sample with corresponding tumor shown below. Peaks are la-
beled with allele call, size in base pairs, and height in relative fluores-
cent units.
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It is then vital to be conservative in interpreting samples 
derived from pathological material.
Since it was determined that in the PowerPlex® system 
the effect of degradation was more pronounced for alleles 
above 350 bp, it is recommended that alleles above this 
size not be considered when conducting statistical analysis 
to determine a forensic match. In alleles of this size, degra-
dation effects cannot be distinguished from true instabili-
ty, namely LOH. This cut-off provides a measure of reliabil-
ity, as it allows the likelihood of degradation alone causing 
false instability determinations to be reduced. Therefore, in 
this system, severe peak imbalance may be indicative of in-
stability, and the locus should be considered for exclusion 
from statistical analysis.
When considering samples amplified with Identifiler®, ge-
netic alterations (cumulative for LOH and MSI) were very 
high in comparison with the same tumor type in the Pow-
erPlex® system. Ninety percent of endometrioid carcino-
mas, 87.5% of papillary serous carcinomas, and 80% of 
mixed tumors exhibited at least one instance of genetic 
instability. Each component of the mixed tumors was con-
sidered separately, as histological differences could reflect 
differences in genetic stability and pathology. The lineage 
and pathway by which these mixed tumor components 
arise is unknown and is currently under investigation. This 
high rate of instability is in concordance with recently 
published results of Heaphy et al (16), who analyzed 239 
different tumor tissues using Identifiler® and found that 
more than 99% of tissues which showed ≥2 instances of 
allelic instabilities were cancerous. Similar to those found 
by PowerPlex® system, instabilities found by Identifiler® in 
our study were not associated with a particular locus. Al-
though intriguing, our results are representative of a small 
and specialized sample set. It is unclear whether this is 
due to the nature of these tumors or related to the sen-
sitivity of the kit as evidenced in our quality analysis stud-
ies. Furthermore, unlike the PowerPlex® system, Identifiler® 
loci showed only weak association between locus size and 
profile quality, making setting a size cut-off for reliability 
problematic.
This increased sensitivity, if due solely to kit sensitivity and 
not the disease itself, presents a problem for blind interpre-
tation (when no histologically normal sample is available 
for comparison) of pathology samples with the Identifiler® 
system. Since Identifiler® appears to be more sensitive to 
detecting genetic instability and the profiles are less sen-
sitive to degradation, a false call due to instability may 
be more easily accepted as the true allele determination, 
thereby causing a false exclusion of a match. Therefore, a 
larger and more diverse sample set should be analyzed in 
this system to provide more specific guidelines.
The natural germline mutation rate of STRs is estimated to 
be between 10−3 and 10−4 per generation (15,17), which is 
low enough to provide the stability and reliability through 
generations for forensic identification and paternity test-
ing. However, these and other STR markers are proven to 
be unstable in various tumor tissues (18,19). LOH and MSI 
are characteristic of many tumors. This instability has been 
demonstrated not only in mono- and di-nucleotide mark-
ers, but in tetra-nucleotide markers as well. Tetra-nucleo-
tide STRs are commonly used in forensic and paternity 
testing, therefore it is vital to determine the genetic stabil-
ity of the forensically relevant loci (20-23). There are mu-
tations and alterations associated exclusively with tumors 
(24-33), which call the reliability of allelic typing with com-
mercially available multiplex kits into question, especially 
in the cases of pathology samples.
In situations where direct comparisons between ques-
tioned and reference samples are made, mutation rates 
are sufficiently low that they may be of minor, although 
not insignificant importance. However, with comparisons 
between relatives in parentage testing and kinship analy-
sis, which may be applied in mass disaster victim iden-
tification, mutational events can play a more significant 
role (34).
Based on the results of this study and other data regard-
ing specific tumor types and its importance for the foren-
sic community, we recommend the following procedure: 
whenever new primer chemistry is introduced and tested 
within forensic community, it is important that the stability 
and reliability of the alleles tested is confirmed in validation 
studies using genetically altered biological material, espe-
cially prior to the situations when it is to be used for the 
analyses of the archival tissues of pathological origin.
Disclaimer
Part of the study reported herein was presented in the form 
of preliminary data as a poster entitled: “Multiplex STR and 
Mitochondrial DNA testing for Paraffin Embedded Speci-
men of Healthy and Malignant Tissues: Interpretation Is-
sues” at the 21st Congress of the International Society of 
Forensic Genetics (ISFG) held at Ponta Delgada, Azores, 
Portugal, September 13-17, 2005.
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